Immunocore Holdings plc financial data

Symbol
IMCR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
90 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Immunocore Ltd (to 2/1/2021)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Operating Margin -23.9 % +19.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.8M shares +3.6%
Common Stock, Shares, Outstanding 50M shares
Entity Public Float 2.7B USD
Common Stock, Value, Issued 135K USD
Weighted Average Number of Shares Outstanding, Basic 49.9M shares +3.52%
Weighted Average Number of Shares Outstanding, Diluted 49.9M shares +3.52%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70.5M USD +29%
Revenue from Contract with Customer, Excluding Assessed Tax 239M USD +69.7%
Cost of Revenue 246K USD +13.9%
Research and Development Expense 57.5M USD +57.1%
Operating Income (Loss) -26.5M USD -80.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24.1M USD -25.7%
Income Tax Expense (Benefit) 357K USD +21.8%
Net Income (Loss) Attributable to Parent -24.4M USD -25.6%
Earnings Per Share, Basic -0.49 USD/shares -22.5%
Earnings Per Share, Diluted -0.49 USD/shares -22.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 833M USD
Accounts Receivable, after Allowance for Credit Loss, Current 57.8M USD
Inventory, Net 4.17M USD
Other Assets, Current 9.71M USD +168%
Assets, Current 926M USD
Deferred Income Tax Assets, Net 10.8M USD
Property, Plant and Equipment, Net 8.38M USD
Operating Lease, Right-of-Use Asset 32.8M USD
Other Assets, Noncurrent 16M USD
Assets 994M USD
Accounts Payable, Current 15.5M USD
Employee-related Liabilities, Current 5.53M USD
Liabilities, Current 155M USD
Operating Lease, Liability, Noncurrent 34M USD
Liabilities 634M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -35.4M USD
Retained Earnings (Accumulated Deficit) -769M USD
Stockholders' Equity Attributable to Parent 360M USD +5.34%
Liabilities and Equity 994M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.59M USD -144%
Net Cash Provided by (Used in) Financing Activities 396M USD +6351%
Net Cash Provided by (Used in) Investing Activities -430K USD +85.7%
Common Stock, Shares, Issued 50M shares
Common Stock, Par or Stated Value Per Share 0 GBP/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 833M USD +99.1%
Deferred Tax Assets, Valuation Allowance 83.1M USD -3.83%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.24 pure +21.1%
Deferred Tax Assets, Gross 95.3M USD +3.09%
Operating Lease, Liability 35.2M USD
Depreciation 1.01M USD +6.2%
Payments to Acquire Property, Plant, and Equipment 430K USD -85.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -23.5M USD -95.9%
Lessee, Operating Lease, Liability, to be Paid 60.1M USD
Property, Plant and Equipment, Gross 61.5M USD +15%
Operating Lease, Liability, Current 1.24M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.84M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.85M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 5.84M USD +238%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 24.9M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.66M USD
Deferred Tax Assets, Operating Loss Carryforwards 74.9M USD +2.54%
Current Income Tax Expense (Benefit) -240K USD +98.2%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.84M USD
Operating Lease, Payments 4.63M USD +17.2%
Additional Paid in Capital 1.16B USD
Depreciation, Depletion and Amortization 4.1M USD -22.6%
Interest Expense 3.24M USD +159%